MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
6.41
+0.08
+1.26%
After Hours: 6.42 +0.01 +0.13% 16:41 08/21 EDT
OPEN
6.36
PREV CLOSE
6.33
HIGH
6.50
LOW
6.29
VOLUME
2.21M
TURNOVER
--
52 WEEK HIGH
6.52
52 WEEK LOW
1.740
MARKET CAP
943.54M
P/E (TTM)
-10.9535
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRS last week (0810-0814)?
Weekly Report · 4d ago
High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Seeking Alpha · 08/10 12:49
Weekly Report: what happened at ACRS last week (0803-0807)?
Weekly Report · 08/10 09:06
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue
Simply Wall St · 08/07 22:27
Aclaris Therapeutics (ACRS) Gets a Buy from Piper Sandler
TipRanks · 08/07 15:27
Aclaris Q2 Net Loss Expands; Secures FDA's Fast Track Designation For Modzatinib In Lichen Planus
NASDAQ · 08/07 05:20
Aclaris Updates At-The-Market Equity Sales Agreement
TipRanks · 08/06 22:22
Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib
Dow Jones · 08/06 21:34
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.